The estimated Net Worth of Gary A. Gelbfish is at least $21.4 million dollars as of 12 October 2018. Gary Gelbfish owns over 1,000,000 units of CorMedix Inc stock worth over $21,428,746 and over the last 15 years Gary sold CRMD stock worth over $0.
Sign up
Gary Gelbfish CRMD stock SEC Form 4 insiders trading
Gary has made over 3 trades of the CorMedix Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Gary exercised 1,000,000 units of CRMD stock worth $1,050,000 on 12 October 2018.
The largest trade Gary's ever made was exercising 1,000,000 units of CorMedix Inc stock on 12 October 2018 worth over $1,050,000. On average, Gary trades about 67,211 units every 156 days since 2010. As of 12 October 2018 Gary still owns at least 3,101,121 units of CorMedix Inc stock.
You can see the complete history of Gary Gelbfish stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Gary Gelbfish's mailing address?
Gary's mailing address filed with the SEC is C/O CORMEDIX INC., 86 SUMMIT AVENUE, SUITE 301, SUMMIT, NJ, 079013647.
Insiders trading at CorMedix Inc
Over the last 15 years, insiders at CorMedix Inc have traded over $693,980 worth of CorMedix Inc stock and bought 2,651,866 units worth $3,532,566 . The most active insiders traders include Mehmood Khan, Gary A. Gelbfish et Brian Lenz. On average, CorMedix Inc executives and independent directors trade stock every 30 days with the average trade being worth of $199,105. The most recent stock trade was executed by Joseph Todisco on 13 March 2024, trading 13,561 units of CRMD stock currently worth $50,718.
What does CorMedix Inc do?
cormedix inc. is a company based out of 745 route 202-206, suite 303, bridgewater, nj, united states.
What does CorMedix Inc's logo look like?
Complete history of Gary Gelbfish stock trades at CorMedix Inc
CorMedix Inc executives and stock owners
CorMedix Inc executives and other stock owners filed with the SEC include:
-
Khoso Baluch,
Chief Executive Officer, Interim Principal Accounting Officer, Director -
Phoebe Mounts,
Executive Vice President, General Counsel, Head of Regulatory, Compliance and Legal -
Elizabeth Masson,
Executive Vice President - Head of Clinical Operations -
Khoso Baluch,
CEO & Director -
Dr. Phoebe Mounts Esq.,
Exec. VP, Gen. Counsel, Sec. and Head of Regulatory, Compliance & Legal -
John Armstrong,
Executive Vice President - Technical Operations -
Elizabeth Masson-Hurlburt,
Exec. VP & Head of Clinical Operations -
John L. Armstrong Jr.,
Exec. VP for Technical Operations -
Alan Dunton,
Independent Director -
Myron Kaplan,
Independent Chairman of the Board -
Steven Lefkowitz,
Independent Director -
Janet Dillione,
Independent Director -
Gregory Duncan,
Director -
Paulo Costa,
Director -
Matthew David,
Chief Financial Officer, Executive Vice President -
Thomas Nusbickel,
Exec. VP & Chief Commercial Officer -
Dr. Paul Chew M.D.,
Acting Chief Medical Officer -
Dr. Paul Chew,
Acting Chief Medical Officer -
Dr. Matthew T. David M.D.,
Exec. VP & CFO -
Judith R Abrams,
Chief Medical Officer -
Robert W. Cook,
Chief Financial Officer -
Taunia Markvicka,
Director -
Antony Pfaffle,
Director -
Randy Milby,
Chief Operating Officer -
Cora M Tellez,
Director -
Mehmood Khan,
-
Michael W George,
Director -
Gary A. Gelbfish,
Director -
James Lefkowitz,
Director -
Bami Bastani,
Director -
Timothy M Hofer,
Secretary -
Mark T. Houser,
Chief Medical Officer -
John C. Houghton,
President and CEO -
Mark A. Klausner,
Chief Medical Officer -
Russell H Ellison,
Director -
Robert A Stewart,
-
Matthew Duffy,
Director -
Harry O'grady,
Chief Financial Officer -
Richard Cohen,
Director -
Development Inc Pharmabio,
10% owner -
Brian Lenz,
Chief Financial Officer -
Thomas Nusbickel,
EVP, Chief Commercial Officer -
Joseph Todisco,
Chief Executive Officer -
Kaufman Beth Zelnick,
Chief Legal Officer -
Erin Mistry,
Chief Commercial Officer